Companies Founded

• Founded in 1995 to develop ligand-targeted medicines.
• Sold EC145, a folate-targeted chemotherapy, to Merck in 2012 for $120 million upfront plus $880 million in potential milestone payments.
• Developed Lu Pluvicto and Locametz for targeted radiotherapy and radioimaging of prostate cancer and obtained both FDA approvals in 2022.
• Was purchased in December 2019 by Novartis for $2.1 billion.

 

• Founded in 2010 to develop tumor-targeted fluorescent dyes for better visualization of malignant tissues during cancer surgeries.
• Raised $150 million to develop these tumor-targeted fluorescent dyes.
• Obtained FDA approval for Cytalux in 2021 based on clinical data showing that it enabled surgeons to find and resect otherwise undetectable cancer in 32% and 54% of ovarian nonsmall cell lung cancer patients, respectively.

 

• Founded in 2017 to develop drugs to accelerate bone fracture healing
• $108 million raised in reverse merger in 2022 with Quince

 

• Founded in 2019 to develop drugs to treat diseases of the human red blood cell
• Created a therapy for malaria in 2016
• Created a therapy for sickle cell disease in 2025

 

• Founded in 2019 to develop CAR T cell therapies for cancers
• ~$273 million raised in series A financing
• $1.44 billion contract signed in 2024 with Abbvie.
• First in vivo manufactured CAR T cell tested in humans in 2025

 

 

• Founded in 2020 to develop drugs to treat viral infections
• ~$30 million raised in Series A
• Created new therapy for influenza infections in 2024
• Created new therapy for respiratory syncytial virus infections in 2025

 

• Founded in 2020 to develop drugs to reprogram the human immune system.
• $170 million raised in Series A and merger with Immunome in 2023

 

• Founded in 2025 as a non-profit institute to accelerate the development of promising drugs from the Low lab by introducing them into human clinical trials in parallel rather than in single file.
• Funded with a $20 million gift from Joan and Phil Low.
• Designed to persist in perpetuity and to facilitate the translation of qualifying drugs from across Purdue University into human use.